Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Martin C. Müller, Jorge E. Cortes, Dong-Wook Kim, Brian J. Druker, Philipp Erben, Ricardo Pasquini, Susan Branford, Timothy P. Hughes, Jerald P. Radich, Lynn Ploughman, Jaydip Mukhopadhyay, Andreas Hochhaus

Blood (2009) 114 (24): 4944–4953.

https://doi.org/10.1182/blood-2009-04-214221

Published: 2009

Includes: Supplemental data

Journal Articles

Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.

Susan Branford, Andreas Hochhaus, Martin Mueller, Erkut Bahceci, Lynn Ploughman, Jaydip Mukhopadhyay, Timothy Hughes

Blood (2009) 114 (22): 3282.

https://doi.org/10.1182/blood.V114.22.3282.3282

Published: 2009

Journal Articles

Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Neil Shah, Erkut Bahceci, Alexandre Lambert, Lynn Ploughman, Jerald Radich

Blood (2009) 114 (22): 1122.

https://doi.org/10.1182/blood.V114.22.1122.1122

Published: 2009

Journal Articles

Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

Martin C Müller, Jorge Cortes, MD, Dong-Wook Kim, MD, PhD, Brian J. Druker, Philipp Erben, MD, Ricardo Pasquini, Timothy P Hughes, MD, Yousif Matloub, Lynn Ploughman, Andreas Hochhaus, MD

Blood (2008) 112 (11): 449.

https://doi.org/10.1182/blood.V112.11.449.449

Published: 2008

Journal Articles

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Michael W.N. Deininger, MD, Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, Jerald Radich

Blood (2008) 112 (11): 3236.

https://doi.org/10.1182/blood.V112.11.3236.3236

Published: 2008

NARROW

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.

Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Email alerts

ASH Publications

American Society of Hematology

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.

Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).

Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only